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Metformin — today’s panacea?
AbstrAct
Metformin is still an immutable basic hypoglycemic 
drug used in pharmacotherapy of diabetes mellitus 
type 2. structurally it belongs to biguanide derivatives 
that was discovered in traditional herbalism. Galega 
officinalis was a plant used to obtain substances similar 
to metformin. this drug can induce a state in a cell, 
which occurs as a result of caloric restriction. It con-
sists in decreasing the effectiveness of IGF-1 metabolic 
pathway with the insulin-like growth factor 1 and 
mtOr kinase activity, thus metformin contributes to 
extend a lifespan among animals. this article presents 
a brief overview of studies about anti-aging potential 
of metformin. beside this, the authors have described 
caloric restriction role taking part in a lifespan as well 
as slowing down incidence of age related diseases. 
(clin Diabetol 2016; 5, 4: 117–122)
Key words: metformin, aging, mtOr kinase,  
IGF-1 pathway, studies
Introduction
The number of elderly people steadily increases in 
recent decades. Primarily, it is a result of a significant 
development of medical science that we have been 
and still are witnessing. We cannot eliminate the ag-
ing process, however its retardation and thus slowing 
down the progress of age-related diseases is to improve 
the quality of life and its extension in good health. We 
cannot forget also about the economic dimension. 
Therefore, there is an upward trend in the number of 
scientific studies concerning the aging process, inter-
ference in the regulation of these processes and their 
most accurate recognition [1]. The scientists are also 
trying to develop new drugs or, what is significant, to 
find anti-aging potential among the drugs widely used 
in medical treatment of other diseases. One of them 
is metformin — a drug having pleiotropic effects in 
the body. The authors of this paper decided to focus 
on its activity. 
Metformin is one of the most popular medicinal 
substances used in pharmacotherapy of diabetes mel-
litus type 2. Metformin monotherapy constitutes the 
first stage of treatment of this disease (together with 
the prescription to modify the lifestyle and reduce the 
calorific value of meals). Moreover, the place of met-
formin at a later stage of therapeutic process among 
other drugs (oral antidiabetics or insulin) is still well 
established [2]. The maximum therapeutic dose of met-
formin is 3000 mg/d and it is administered mostly in 3 
divided doses. Its discovery dates back to Middle Ages, 
when the use of Galega officinalis in the traditional 
herbal medicine was associated with the treatment 
of symptoms resulting from diabetes mellitus type 2 
[3]. Nevertheless, the clinical antidiabetic effect of 
metformin was discovered and proved in the 60’s of 
the twentieth century, in the research carried out under 
the guidance of a French physician — Jean’a Sterne’a 
[4]. However, the clinical indications for the use of bi-
guanide derivative do not limit only to the treatment 
of diabetes mellitus type 2. We should also mention 
the pre-diabetes condition, metabolic syndrome (or its 
components, including insulin resistance), polycystic 
ovary syndrome and lipodystrophy [5]. 
Among the current scientific studies concerning 
other uses of metformin, its anti-tumour and anti-aging 
activity is still mostly subject to evaluation. A growing 
number of reports in this regard proves that both the 
scientists and clinical practitioners are more and more 
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interested in this issue. The fact is that, metformin has 
proven to be a drug which, during its use by patients 
with diabetes mellitus type 2, is also associated with 
a reduced risk of cancer and cardiovascular disorders. 
The efficacy of metformin in these diseases shows that 
it is possible to use a biguanide derivative in other dis-
eases, and what is more, its anti-aging activity cannot 
be excluded per se [6]. 
Caloric restriction
Moderate caloric restriction is considered as the ma-
jor modifiable factor which most significantly contrib-
utes to the prolongation of life in good health, reduces 
the incidence of diseases associated with age and it 
determines a better quality of life [7, 8]. The biochemi-
cal pathway with the somatotropic axis, i.e. the growth 
hormone, GH and insulin-like growth Factor 1, IGF-1 is 
one of the main biochemical pathways that actuate in 
response to a specific “sensor” (that is, nutrients). This 
pathway, together with the intensively secreted insulin 
after a meal, besides the synchronization of develop-
ment and growth of the organism, constitutes one of 
the most important pathogenesis (additionally to DNA 
damage, telomere shortening, response to stress and 
chronic inflammation) involved in longevity [9]. IGF-1 
is one of the main anabolic substances in the body. It 
affects the growth of cells, and by preventing apoptosis, 
it determines also the lifespan and stimulates cellular 
differentiation. Paradoxically, an increase of IGF-1 (e.g. 
stimulated by ingestion) does not prevent aging, but 
it is the reduction of the level of growth hormone and 
IGF-1 that facilitates longevity. It has been proven that 
mice with growth hormone deficiency live longer. A 
greater resistance to stress and increase in the synthesis 
of antioxidant enzymes has been observed among the 
mice. Although a complete suppression of the pathway 
dependent on IGF-1 proved to be lethal, the reduction 
of its activity results in prolongation of life in mice [10].
The genes that regulate the activity of a protein cascade 
involving IGF-1 and influencing the extension of life 
include, among others, daf-2 (others are age-1, age-2, 
akt-1), which encodes the protein with a homonymous 
name. This peptide being evolutionary conservative, is 
the key regulator of the intracellular cascade involving 
IGF-1 [11]. The scientific reports concerning humans also 
points at few genes associated with the GH/IGF-1 axis 
and affecting the length of life. The greatest importance 
is attributed to a variant of FOXO3A gene that is more 
common in people older than 100 years. This gene is 
considered to be homologue to the daf-16 gene that 
cooperates with daf-2 in Caenorhabditis elegans [12]. 
Moreover, mutations of the receptor for IGF-1 are also 
noteworthy [32]. 
The pathway involving IGF-1 indirectly leads also 
to an increase in the activity of mTOR kinase. This 
protein from the group of serine-threonine kinases is 
stimulated by IGF-1 involving an intermediate molecule, 
i.e. phosphatidylinositol. mTOR kinase is one of the key 
intracellular factors participating in the modulation 
of the growth, proliferation and metabolism of a cell. 
It happens in response to signals from the activated 
membrane receptors. In addition, oxygen and/or energy 
substrates concentration in a cell is also important. 
The purpose of mTOR kinase is the phosphorylation of 
transcription factors responsible for the biosynthesis 
of the ribosomal protein. A pathological increase in its 
activity has been found in many diseases, in particular 
those related to cancer, and nowadays, it indirectly but 
strongly determines the lifespan [14]. In order to explain 
these phenomena, we have to go to the molecular level 
of a cell, at which mTOR kinase affects the cell cycle 
progress by biosynthesis of protein necessary for the 
production of cyclin D1. It causes transition of the cell 
from phase G1 to the cell division cycle S. Additionally, 
this type of kinase can also inhibit apoptosis. It happens 
by promoting the expression of protein being a member 
of apoptosis inhibitors family, the so-called survivin 
[15–17]. It is of vital importance that at the time of 
low energy level of the cell, the AMP-activated kinase 
(AMPK) stops the signalling depending on mTOR kinase. 
There is a hypothesis regarding many living organisms 
that the reduction of mTOR kinase activity may have 
a positive effect on the inhibition of cell proliferation 
and vitality [18]. This dependency was proved, among 
others, in the studies in heterogeneous mice. Starting 
from 600 day of life of animals, the inhibition of the 
pathway involving mTOR kinase by using rapamycin 
(mTOR kinase inhibitor) resulted in prolongation of 
their life by 9–14% [19]. 
Biochemically, the essential purpose of the caloric 
restriction is to reduce the activity of the signalling 
pathway involving IGF-1 and mTOR kinase activity. 
Reducing insulinemia and increasing insulin sensitivity 
of cells is intrinsically related to the reduction of calorie 
intake. In the studies by Roth et al., longer life among 
men with lower insulin concentration in the blood has 
been found. Moreover, a reduced transmission in the 
path involving IGF-1 is associated with reduced body 
weight and also reduced mortality among women [20, 
21]. Apart from caloric restrictions, it is pointed out that 
the assessment of nourishment in terms of quality is 
also very important. Slim volunteers (average BMI 23.6 
kg/m2) from the association Calorie Restriction Society 
took part in the studies by Hollosza et al., believing 
that caloric restriction has the potential to extend life. 
A diet with a daily caloric restriction was recommended 
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to the volunteers who were observing it for 6.5 years. 
Furthermore, their diet was rich in nutrients exceeding 
even 100% of the recommend daily intake (vegetables, 
fruits, egg whites, lean meat, fish, grains, nuts). After 
completion of the research, it turned out that the aver-
age BMI of the participant was reduced to 19.6 kg/m2 
[22]. What is more, the risk of occurrence of diabetes 
mellitus type 2 among them, as well as atherosclero-
sis, left ventricular dysfunction and hypertension was 
comparatively low with the same risk documented in 
monkeys and rats that were subject to caloric restriction 
[23, 24].The same dependency was found in the context 
of biochemical parameters of blood in these volunteers 
(concentration of total cholesterol as well as LDL and 
HDL, glycaemia, insulinemia, CRP) compared to people 
who are on a typical American diet [24]. In the same 
year, the studies by Willcox and et al. were published. 
They concerned the influence of caloric restriction on 
health and lifespan of Japanese from Okinawa. This 
research group was of special interest because this 
island was occupied by the US (from World War II up 
to 1972). Therefore, the diet of its inhabitants included 
mainly plant-origin products and was low in meat and 
fish. I turned out that the total caloric value of this 
nourishment was lower by 11% than the diet of other 
Japanese. The results clearly showed that the average 
life expectancy of women and men from Okinawa is 
higher than of other inhabitants of the Land of the 
Rising Sun. Also the number of centenarians from this 
island is about 4 times higher than among the inhabit-
ants of other well-developed countries. Moreover, the 
native Japanese from this island not only live longer 
but they also later and less likely fall for cancer and 
cardiac diseases [25].
Caloric restriction — imitation of this  
condition by metformin
Nowadays, the caloric restriction seems to be 
simple only theoretically. In order to achieve the above-
mentioned results, it should consist of reduction of ca. 
30–40% daily ration of food depending on gender and 
daily activities. To enhance the clinical effect of caloric 
restriction and/or to replace it, the substances which 
are to exert the effect similar to caloric restriction are 
used. Longo et al. pre-divided drugs with the potential 
to imitate this effect as to their mechanism of action. 
The first group relates to the mechanisms of action 
of drugs at the gene level, responsible for reduction 
of GH and IGF-1 secretion. Another group was to act 
by inhibiting the release of IGF-1 from hepatocyte. 
Furthermore, the substances that directly influence 
the signalling pathway IGF-1 and causing reduction 
of concentration of its final products or substances 
that mediate this process were also distinguished in 
the report [26, 27]. 
From the pathophysiological point of view, met-
formin works as caloric restriction, resulting in the 
reduction of the energy state of the cell. Consequently, 
the ratio of AMP to ATP increases in the cell. This leads 
to the activation of AMPK which is considered as the 
energy “sensor” in the cell. Thus, the anabolic processes 
are inhibited, inclusive of gluconeogenesis. The profile 
of a liver cell switches to catabolic and opposite pro-
cesses intensify, i.e. fatty acid oxidation (phosphoryla-
tion of acetyl-CoA) and glycolysis. The body weight of 
patients who take metformin does not increase, quite 
the contrary, some reports documents its reduction. The 
improvement of parameters of glycaemia, insulinemia 
and the parameters concerning lipid metabolism is 
one of the numerous beneficial effects of this drug. 
Increasingly reported reduced risk of cancer is another 
effect of the biguanide derivative. This and other effects 
of metformin which are counterweight to the aging 
process have been presented in Table 1 [28–31]. 
Research overview
One of the first reports concerning the role of bi-
guanide derivatives as a geroprotector was presented 
about 40 years ago [32]. Currently, their action prolong-
ing life was proved in numerous observations carried 
out on model animals. The study of Anisimov et al. 
carried out on female transgenic mice of HER-2/neu 
line showed that after application of metformin 
100 mg/kg, the average lifespan of test animals extend-
ed by ca. 8–13% and a maximum of 1 month. What is 
more, a slower increase of glycaemia and triglycerides 
concentration in the blood, reduction of total choles-
terol and b-lipoprotein compared to the control group 
table. 1. Metformin effect mitigating the changes at the 
molecular and tissue level occurring during aging










Risk of cancer 
Life expectancy
ROS — reactive oxygen species; AGEs — advanced glycation end products 
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was observed within the test group [33]. A few years 
later, another study on mice of the same line was car-
ried out under the guidance of the same author, and it 
showed a similar percentage of life extension in animals 
treated with metformin. Furthermore, in the context 
of anticancer potential of this drug, it was observed 
that breast adenoma occurs 10% later, and the use of 
metformin in combination with melatonin proved to 
reduce the growth of Ehrlich tumour (causing ascites 
in laboratory animals) by more than 40% [34]. The 
same author used female mice from an outbred line in 
another research, assessing the anti-aging potential of 
metformin. The animals from the research group tak-
ing metformin (100 mg/kg b.w.) reduced body weight, 
despite a slight reduction in food consumption. The 
average length of their life increased by more than 35% 
and the maximum lifespan increased by ca. 10% (by 
more than 2.5 month). The time in which mice were 
fertile has also been extended. Nevertheless, no anti-
cancer role of metformin was found in this report [35]. 
In the context of the size of the anti-aging po-
tential of metformin, the sex of animals proved to 
be also of vital importance. It has been proven that 
among female mice of 129/Sv line, a chronic therapy 
with metformin extended their lives by ca. 5%. Such 
an effect has not been observed among males of the 
species, quite the contrary, the average of their lifespan 
has been reduced by more than 10%. The same occurs 
in terms of the anti-cancer role of metformin. The inci-
dence of malignant tumours has reduced 3.5 times in 
females, and it has not been observed in males of this 
species [36]. The purpose of another research was to 
answer the question, when does the commencement 
of therapy with metformin determine the lifespan 
to the greatest extent. For this purpose, the age of 
animals at which the therapy with this drug was com-
menced was evaluated. The research group consisted 
of 3 groups. In the first group, metformin was started 
to be given to mice at the age of three months. The 
second group commenced the therapy after reaching 
the age of 9 months, and the last one at the age of 
1 year and 3 months. As it turned out, the therapy with 
metformin delayed disruption of reproductive func-
tions in each of these groups. Additionally, this therapy 
did not contributed significantly to the change of 
concentration of cholesterol and glycaemia in none of 
the groups. With regard to the anti-aging effect, it was 
shown in the study that the earlier the therapy with 
metformin is started, the greater potential to extend 
life is achieved (14% and 6% in the first and second 
group, respectively). In the third group, in which the 
metformin therapy was started at the latest, no pro-
longation of life under the influence of this drug has 
been observed. Retardation of development of cancer 
diseases was noticed also only in two first groups [37]. 
Some of the latest reports of Anisimov et al. consti-
tutes, to some extent, a continuation of the previous 
one. According to the hypothesis of the author, the 
perinatal age constitutes the major determinant in the 
development of hypothalamic mechanisms controlling 
the energy homeostasis. Following this reasoning, 
thanks to the mechanism of action of metformin (that 
is incorporated into the therapy at that time) it is pos-
sible to delay the onset of age-related diseases. In the 
study, metformin was administered to the male and 
female mice of line 129/Sv, SC on 3rd, 5th and 7th day 
after birth. The results show that the amount of food 
eaten by male decreased and their lower body weight 
(compared to the control group) has maintained for 
the entire life. It is also interesting, that the average 
lifespan of male receiving metformin extended by 
about 20%, and the maximum lifetime by 3.5%. No 
such effect has been observed in female. Their average 
life expectancy decreased by ca. 14% in the research 
group. The endpoint of the study was reaching the 
age of 800 days, and almost half male of the control 
group and nearly 75% of the research group lived till 
that time. Slightly more than 50% of female mice of the 
control group and only 1/3 of the research group lived 
till that time [38]. The results of the research carried 
out by the Research Team from the National Institute 
on Ageing, Baltimore (USA) present the correlation 
of the applied metformin dose on the size of the ef-
fect prolonging life. After the animals approach the 
middle-age (600 days), metformin was administered 
to them in concentration of 0.1% and 1% of the diet 
weight fraction. It was found after several months of 
the study that males taking a lower dose of the drug 
lived longer by 5% than mice that did not receive the 
drug. Moreover, they also characterized with a lower 
frequency of incidence of circulatory system disorders. 
Conversely is with the mice that were given a higher 
dose of metformin. They were dying faster than mice 
from both groups subject to the research. According 
to the authors of the study, these dependencies can 
be explained with the claim that metformin applied in 
low doses mobilizes the body to work more efficiently 
with a reduced amount of produced reactive oxygen 
species that damage cells and tissues of the body [39].
The report of Onken et al. based on C. elegans 
documents also the relationship between the met-
formin dose taken and the achieved different length of 
life. A slight increase of the maximum life expectancy 
with a strong influence on the average age of these 
nematodes was achieved with the application of only 
50 mmol/l of metformin. The desired effects with ap-
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plication of a lower dose (10 mmol/l) and a greater 
dose (100 mmol/l) were negligible [40].
Taking the abovementioned issues into account, 
among the clinical tests those carried out by Bannister 
et al. are noteworthy. The report showed that patients 
with diabetes mellitus type 2 and regularly receiving 
metformin in the monotherapy characterize with even 
more than 15% longer life than people without dia-
betes and who do not take metformin. This peculiar 
paradox observed in this study strongly encouraged 
scientists to determine the potential of metformin to 
prolong lives of people [41]. 
The hopes of clinicians in determining the anti-
aging role of metformin in the strict sense is associated 
with the recently launched TAME study (Targeting Ag-
ing with Metformin). The study that is financed by the 
American Federation for Aging Research is spearheaded 
by Dr. Barzilai. A double-blind, placebo-control study 
will be the first such clinical and scientific trial determin-
ing the anti-aging potential of metformin. Its premise 
is to administer this drug to 3000 patients who are 
between the 7th and 8th decade of life. Only the patients 
who suffer one or two of these three age-related dis-
eases, i.e. heart diseases, malignant tumour or cognitive 
impairment, may take part in the research. The study is 
intended to answer the question, whether metformin 
has the ability to inhibit the progress of such diseases 
and delay mortality associated with these disorders. 
It is significant in this research that the patients with 
diabetes mellitus type 2 are not qualified to participate, 
because the assumption of the authors is that presum-
ably, they have been treated with metformin for an 
indefinite period of time. Consequently, it could bring 
inadequate results of this study. What is more, the study 
also aims to answer the question, whether a long-term 
treatment with metformin of patients without diabetes 
mellitus type 2 is safe (Fig. 1) [42–44]. 
Summary
Metformin is one of the most widely prescribed 
drug in the world. Pharmacies receive more than 120 
million prescriptions for this drug yearly [45]. Undoubt-
edly, it has a pleiotropic effect in the body and it is 
advisable to search for its new applications. One of 
them is the anti-aging activity of metformin. Success-
ful results of animal research induce the scientists to 
boldly apply these effects also to the people. However, 
clinical research and more extensive data on the subject 
are required to confirm the above. The authors of the 
study are eagerly waiting for the results of the TAME 
project which can be somehow the beginning of an 
avalanche of studies concerning the anti-aging poten-
tial of metformin among the people. The biochemical 
basis for metformin effect and its imitation of caloric 
restriction, which in itself has an undeniable anti-aging 
effects, may justify that this drug can in a well-known 
manner logically explain the anti-aging effect.
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